Understanding the diversity and biogeography of Colombian edible plants.

Despite being the second most biodiverse country in the world, hosting more than 7000 useful species, Colombia is characterized by widespread poverty and food insecurity. Following the growing attention in Neglected and Underutilized Species, the present study will combine spatial and taxonomic analysis to unveil their diversity and distribution, as well as to advocate their potential as key resources for tackling food security in the country. The cataloguing of Colombian edible plants resulted in 3805 species. Among these, the most species-rich genera included Inga, Passiflora, Miconia, Solanum, Pouteria, Protium, Annona and Bactris. Biogeographic analysis revealed major diversity hotspots in the Andean humid forests by number of records, species, families, and genera. The departments of Antioquia, Boyacá, Meta, and Cundinamarca ranked first both in terms of number of unique georeferenced records and species of edible plants. Significant information gaps about species distribution were detected in the departments of Cesar, Sucre, Atlántico, Vichada, and Guainía, corresponding to the Caribe and Llanos bioregions, indicating the urgent need for focusing investigation in these areas. Furthermore, a significant level of geographic specificity was found in edible plant species' distributions between 13 different bioregions and 33 departments, hinting the adoption of tailorized prioritisation protocols for the conservation and revitalization of such resources at the local level.

Safety and efficacy of oral vinorelbine and capecitabine combination for metastatic breast cancer.

The aim of this prospective open-label study was to evaluate the efficacy and safety of oral vinorelbine in combination with capecitabine in patients with metastatic breast cancer (MBC). 51 patients with MBC received oral vinorelbine and capecitabine. The safety profile was analyzed through NCI-CTCAE v3.0 and response was evaluated using RECIST criteria. The overall response rate was 37.2%: there were four complete responders (8%) and fifteen partial responders (29.4%); practically all the responders were patients previously treated with anthracyclines and taxanes. Sixteen patients (31.3%) experienced stable disease. The clinical benefit rate was 68.5%. The median time to progression was 8 months (range 2-43; 95% CI: 6-10.8). Vinorelbine in combination with capecitabine is an effective and safe schedule for patients with MBC especially after pretreatment with anthracycline/ taxane-based regimens. The clinical benefit suggests that this may be a promising schedule in the MBC initial treatment.